Patient-reported outcomes (PROs) from MARIANNE: A phase III study of trastuzumab emtansine (T-DM1) +/- pertuzumab (P) vs trastuzumab plus taxane (HT) for HER2-positive advanced breast cancer.

Affiliation auteurs!!!! Error affiliation !!!!
TitrePatient-reported outcomes (PROs) from MARIANNE: A phase III study of trastuzumab emtansine (T-DM1) +/- pertuzumab (P) vs trastuzumab plus taxane (HT) for HER2-positive advanced breast cancer.
Type de publicationJournal Article
Year of Publication2016
AuteursBarrios CH, Cella D, Martin M, Eiermann W, Burris HA, Im Y-H, Conte PFranco, Toi M, Pienkowski T, Pivot XB, Beckermann B, Stanzel SFranz, Petersen J, Ellis PAnthony
JournalJOURNAL OF CLINICAL ONCOLOGY
Volume34
Date PublishedMAY 20
Type of ArticleMeeting Abstract
ISSN0732-183X
DOI10.1200/JCO.2016.34.15_suppl.593